CardioPep Pharma GmbH

CardioPep Pharma GmbH is a subsidiary of Pharis Biotec GmbH. The goal of CardioPep Pharma GmbH is to develop the endogenous natriuretic peptide URODILATIN (INN: Ularitide) for the treatment of decompensated congestive heart failure (CHF) and other indications. Based on its diuretic, natriuretic, vasodilatory, and bronchodilatory properties, URODILATIN is considered highly suitable for treating patients with decompensated CHF.